FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for STEGLUJAN, a fixed-dose combination of ertugliflozin and sitagliptin, developed by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)

Snippet

SUPPL AP for STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)